Abstract: Restless legs syndrome (RLS) is characterized by an urge for leg movement, often with abnormal leg sensations. Symptoms are triggered by rest, often at night, and improve temporarily with movement, especially walking. This syndrome has a prevalence ranging from 7% to 15% and significantly contributes to sleep disorders. A method of prevention of restless legs syndrome is disclosed that comprises orally administering a composition containing a therapeutically effective amount of rifaximin to a patient exhibiting symptoms of restless legs syndrome.

Abstract: Chronic prostatitis (CP) is a syndrome characterized by pelvic pain in one or more areas (perineum, lower abdominal, testicular and/or penile), urinary frequency, urinary urgency, sexual dysfunction and/or ejaculatory pain. CP type IIIa is the most common type of prostatitis and is defined by having sterile EPS and a leukocyte count greater than 1000/mm2. A method of prevention of chronic prostatitis is disclosed that comprises orally administering a composition containing a therapeutically effective amount of rifaximin to a patient exhibiting symptoms of chronic prostatitis.